trial

Treatment of Psychotic Major Depression With Mifepristone

NCTId NCT00867360
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 10 (actual)
Sponsored by Stanford University
Primary completion 2009-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
10 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Triple
Start
2005-08
Primary completion
2009-05
Eligibility
ALL · 21 Years · 85 Years

Interventions & indications

Drugs
Mifepristone (RU-486)

Sponsors

Stanford UniversityLead Sponsor

Investigators

1
Fredric B KraemerPrincipal Investigator

Sites

1 total
Stanford, United States

Linked catalysts

1
Treatment of Psychotic Major Depression With Mifepristone — primary completion2009-05

Facts & assertions

4 sourced
Enrollment
10
Phase
PHASE3
Primary Completion Date
2009-05
Status
TERMINATED
relationships
The graph out of here
drug
Mifepristone (RU-486)
drug
lead_sponsor
Stanford University
company
indication
Affective Disorders, Psychotic
indication
Depressive Disorder
indication
Depressive Disorder
indication
investigator
Fredric B Kraemer
person